Gregor Fuhrmann on ORCID 0000-0002-6688-5126 and on Google Scholar
74. Dorfner M, Mifka A, Maia de Pádua R, Thaís da Silva I, Zanella Guterres I, Sana L, Fuhrmann G & Munkert J (2025) Cardenolide-engineered extracellular vesicles augment drug uptake and cytotoxicity in non-small cell lung cancer cells Small Methods in press
73. Drost M & Fuhrmann G* (2025) Pseudomonas aeruginosa and its unsuspected ally Lactiplantibacillus plantarum: enhanced pathogenicity in a combined Cystic Fibrosis sputum − epithelial cell model ACS Infectious Diseases in press (published as part of the special issue “The Role of Microbiota in Infections and Immunity”)
72. D’Antoni C, Pourtalebi Jahromi L, Sana L, Domínguez Rubio AP, Dorfner M, Munkert J, Danzer H, Arnold P, Lebedev M, Zanin E, Pérez OE & Fuhrmann G* (2025) Membrane vesicles from Lacticaseibacillus casei BL23 exhibit antimicrobial activity against Escherichia coli and immunostimulatory effects on human peripheral blood mononuclear cells Advanced Healthcare Materials in press
71. Arnold P […] Fuhrmann G […] Günther C (2025) Two sides of the same coin - Mechanistic insight, Diagnostic application and Therapeutic translation of Bacterial and Host derived Extracellular Vesicles. Journal of Extracellular Biology https://doi.org/10.1002/jex2.70093
70. Pourtalebi Jahromi L, Kronast B, Munkert J, Sana L [...] Zaiss MM, Fuhrmann G* (2025) Bioengineered Bacterial Vesicles and Biomimetic Hybrids Eliminate Biofilms and Balance the Gut Microbiome. Small https://doi.org/10.1002/smll.202502551
69. Kardani A [...] Hoppstädter J, Fuhrmann G* & Kiemer AK (2025) Laminar Flow Alters EV Composition in HUVECs: A Study of Culture Medium Optimization and Molecular Profiling of Vesicle Cargo. Small Methods https://doi.org/10.1002/smtd.202401841
68. Hildebrand LS, Jost T, Schindler M, Derer A, Fuhrmann G, Fietkau R & Distel LV (2025) Inhibting NHEJ in HNSCC cell lines by the ligase IV inhibitor SCR130 has limited radiosensitising effects. Sci Rep https://doi.org/10.1038/s41598-025-03159-5
67. Pourtalebi Jahromi L & Fuhrmann G* (2025) A chemical toolbox for surface engineering of extracellular vesicles. Nat Rev Bioeng https://doi.org/10.1038/s44222-025-00310-9
66. Pitakbut T, Munkert J, Xi W, Wei Y & Fuhrmann G (2025) A dataset for machine learning-based QSAR models establishment to screen beta-lactamase inhibitors using the FARM -BIOMOL chemical library. BMC Research Notes https://doi.org/10.1186/s13104-025-07159-6
66. Pitakbut T, Munkert J, Xi W, Wei Y & Fuhrmann G (2024) Utilizing machine learning-based QSAR model to overcome standalone consensus docking limitation in beta-lactamase inhibitors screening: a proof-of-concept study. BMC Chemistry https://doi.org/10.1186/s13065-024-01324-x
65. Dorner H, Stolzer I, Mattner J [...] Fuhrmann G [...] Günther C (2024) Gut Pathobiont–Derived Outer Membrane Vesicles Drive Liver Inflammation and Fibrosis in Primary Sclerosing Cholangitis–Associated Inflammatory Bowel Disease. Gastroenterology https://doi.org/10.1053/j.gastro.2024.06.032032
64. Mashayekhi V [...] Fuhrmann G, Hoppstätter J & Kiemer AKK (2024) The RNA binding protein IGF2BP2/IMP2 alters the cargo of cancer cell-derived extracellular vesicles supporting tumor-associated macrophages. Cell Communication and Signalling 22:344
63. Bettin I [...] Fuhrmann G, Mariotto S & Butturini E (2024) Extracellular Vesicles based STAT3 delivery as innovative therapeutic approach to restore STAT3 signaling deficiency. New Biotechnology 82:43
62. Poupardin R, Wolf M, Maeding N, Paniushkina L, Geissler S, Bergese P, Witwer KW, Schallmoser K, Fuhrmann G & Strunk D (2024) Advances in Extracellular Vesicle Research Over The Past Decade: Source And Isolation Method Are Connected with Cargo And Function. Advanced Healthcare Materials https://doi.org/10.1002/adhm.202303941
61. Kuhn T, Aljohmani A [...] Yildiz D, Fuhrmann G (2024) A cell-free, biomimetic hydrogel based on probiotic membrane vesicles ameliorates wound healing. Journal of Controlled Release 365:969
This work is part of the Special Issue on Extracellular Vesicles (EVs) and Hybrid Systems, a collection of high-quality research and review articles from researchers working on EVs and hybrid systems.
60. Jahromi LP, Rothammer M & Fuhrmann G (2023) Polysaccharide hydrogel platforms as suitable carriers of liposomes and extracellular vesicles for dermal applications. Advanced Drug Delivery Reviews 200:115028
This contribution is part of the themed issue "Emerging voices in drug delivery"
59. Kern F, Kuhn T [...] Fuhrmann G, Wyss-Coray T, Meese E, Keller V, Laschke MW & Keller A (2023) Ageing-associated small RNA cargo of extracellular vesicles. RNA Biology in print https://doi.org/10.1080/15476286.2023.2234713
58. Heinrich E, Hartwig O, Walt C, Kardani A, Koch M, Jahromi PL, Hoppstädter J, Kiemer AK, Loretz B, Lehr C-M & Fuhrmann G* (2023) Cell-derived vesicles for antibiotic delivery - understanding the challenges of a biogenic carrier system. Small 19:2207479 https://doi.org/10.1002/smll.202207479
57. Fuhrmann G* (2023) Drug delivery as a sustainable avenue to future therapies. Journal of Controlled Release 354:746 doi.org/10.1016/j.jconrel.2023.01.045
This work was highlighted in Nature Reviews Bioengineering Implementing sustainability in academic research doi.org/10.1038/s44222-023-00043-7
56. Zivko C, Witt F, Koeberle A, Fuhrmann G* & Luciani P* (2022) Formulating elafibranor and obeticholic acid with phospholipids decreases drug-induced association of SPARC to extracellular vesicles from LX-2 human hepatic stellate cells. European Journal of Pharmaceutics and Biopharmaceutics doi.org/10.1016/j.ejpb.2022.11.025
55. Lapuhs P, Heinrich E, Garcia R, Goes A, Frank N, Bollenbach L, Stibane V, Kuhn T, Koch M, Kiemer AK, Müller R, Fuhrmann K & Fuhrmann G* (2022) The
inherent antibiotic activity of myxobacteria-derived
autofluorescent outer membrane vesicles is switched on and off by light stimulation. Nanoscale doi.org/10.1039/D2NR02743G
54. Zivko C, Fuhrmann K, Fuhrmann G* & Luciani P* (2022) Tracking matricellular protein SPARC in
extracellular vesicles as a non-destructive method to evaluate lipid-based antifibrotic treatments. Communications Biology doi.org/10.1038/s42003-022-04123-z
53. Mehanny M, Boese A, Bornamehr B, Hoppstädter J, Presser V, Kiemer AK, Lehr CM & Fuhrmann G* (2022) Spray-dried Pneumococcal Membrane Vesicles are Promising Candidates for Pulmonary Immunization. International Journal of Pharmaceutics doi.org/10.1016/j.ijpharm.2022.121794
52. Nguyen J & Fuhrmann G (2022) Extracellular vesicles - A versatile biomaterial. Advanced Haelthcare Materials 11:2200192
51. Drost M, Diamanti E, Fuhrmann K, Goes A, Shams A, Haupenthal J, Koch M, Hirsch AKH & Fuhrmann G* (2022) Bacteriomimetic liposomes improve antibiotic activity of a novel energy-coupling factor transporter inhibitor. Pharmaceutics doi.org/10.3390/pharmaceutics1401000447
50. Richter R [...] Fuhrmann G, Pages JM, Lehr CM (2021) An Outer Membrane Vesicle-Based Permeation Assay (OMPA) for Assessing Bacterial Bioavailability. Advanced Healthcare Materials, 2101180
49. Krämer-Albers EM, Pogge von Strandmann E, Fuhrmann G, Nazarenko I, Giebel B, Pfaffl M (2021) Meeting report of the 4th autumn meeting of the German Society of Extracellular Vesicles (GSEV): cutting edge EV research driven by young scientists. Extracellular Vesicles and Circulating Nucleic Acids doi.org/10.20517/evcna.2021.23
48. Fuhrmann G*, Lehr CM & Schiffelers R (2021) Extracellular vesicles in drug delivery and bioengineering. Advanced Drug Delivery Reviews 181, 114073
47. Fuhrmann G*, Loretz B, Schneider-Daum N & Lehr C-M (2021) Biobarriers 2018. European Journal of Pharmaceutics and Biopharmaceutics 158:52
46. Mehanny M, Kroniger T, Koch M, Hoppstädter J, Becher D, Kiemer AK, Lehr C-M & Fuhrmann G* (2021) Yields and immunomodulatory effects of pneumococcal membrane vesicles differ with the bacterial growth phase. Advanced Healthcare Materials doi.org/10.1002/adhm.202101151
45. Goes A, Vidakovic L, Drescher K & Fuhrmann G* (2021) Interaction of myxobacteria-derived outer membrane vesicles with biofilms: antiadhesive and antibacterial effects. Nanoscale https://doi.org/10.1039/D1NR02583J
44. Trenkenschuh E, Richter M, Heinrich E, Fuhrmann G & Friess W* (2021) Enhancing the Stabilization Potential of Lyophilization for Extracellular Vesicles.
Advanced Healthcare Materials doi.org/10.1002/adhm.202100538
43. Herrmann IK, Wood M & Fuhrmann G* (2021) Extracellular vesicles as next generation drug delivery platform. Nature Nanotechnology, 16:748
42. Mehanny M, Lehr C-M & Fuhrmann G* (2021) Extracellular vesicles as antigen carriers for novel vaccination avenues. Advanced Drug Delivery
Reviews doi.org/10.1016/j.addr.2021.03.016 41.
Pourtalebi Jahromi L & Fuhrmann G* (2021) Bacterial Vesicles as Underexplored Source for Novel Drug Carriers. Advanced Drug Delivery Reviews
doi.org/10.1016/j.addr.2021.03.012
40.
Richter M, Vader P & Fuhrmann G* (2021) Approaches to surface engineering of extracellular vesicles. Advanced Drug Delivery Reviews doi.org/10.1016/j.addr.2021.03.020
39. Trousil J, Aryal S & Fuhrmann G (2021) Biogenic and biomimetic nanocarrier-based interventions: Focus on intracellular
infections. Nanomedicine, doi.org/10.2217/nnm-2021-0052
38. Müller, L Kuhn T, Koch M & Fuhrmann G* (2021) Stimulation of Probiotic Bacteria Induces Release of Membrane Vesicles with Augmented Anti-inflammatory Activity.
ACS Applied Bio Materials, doi.org/10.1021/acsabm.0c01136
37. Kuhn T, Koch M & Fuhrmann G* (2020) Probiomimetics—Novel Lactobacillus‐Mimicking Microparticles Show Anti‐Inflammatory and Barrier‐Protecting Effects in
Gastrointestinal Models. Small, doi.org/10.1002/smll.202003158
36. Whitworth DE, Jurkevitch E, Perez J, Fuhrmann G & Koval SF (2020) Mechanisms of Prokaryotic Predation. Frontiers in Microbiology doi:10.3389/fmicb.2020.02071 35. Fuhrmann G* (2020) Diffusion and transport of extracellular
vesicles. Nature Nanotechnology, doi: 10.1038/s41565-020-0651-3
34. Zivko C, Fuhrmann G* & Luciani P* (2020) Liver-derived extracellular vesicles: a
cell-by-cell overview to isolation and characterization. Biochimica et Biophysica Acta, doi: 10.1016/j.bbagen.2020.129559
33. Mehanny M, Koch M, Lehr C-M & Fuhrmann G* (2020) Streptococcal extracellular membrane vesicles are rapidly internalized by immune cells and alter their cytokine release. Frontiers in Immunology, 11:80
32. Goes A, Lapuhs P, Kuhn T, Schulz E [...] & Fuhrmann G* (2020) Myxobacteria-derived outer membrane vesicles: potential applicability against intracellular infections. Cells, 9:194
31. Montefusco-Pereira C, Formicola B, Goes A [...] Fuhrmann G, Caneva E, Nicotra F, Lehr C-M (2020) Coupling quaternary ammonium surfactants to the surface of liposomes improves both antibacterial efficacy and host cell biocompatibility. European Journal of Pharmacy and Biopharmacy, 149:12
30. Schulz E, Karagiannis A & Fuhrmann G* (2020) Hot EVs – how temperature affects extracellular vesicles. European Journal of Pharmacy and Biopharmacy, 146:55
29. Woith E, Fuhrmann G* & Melzig MF* (2019) Extracellular Vesicles – Connecting Kingdoms. International Journal of Molecular Sciences, 20:5965
28. Hoppstädter J, Dembek A, Barghash A, Fecher-Trost C, Fuhrmann G, Koch M, Kraegeloh A, Huwer H, Kiemer AK (2019) Toll-like receptor 2 release by macrophages: an anti-inflammatory program induced by glucocorticoids and lipopolysaccharide. Frontiers in Immunology 10:1634
27. Richter M, Fuhrmann K & Fuhrmann G* (2019) Evaluation of the storage stability of extracellular vesicles. Journal of Visualized Experiments, 147:e59584
See the full video protocol here.
26. Thery C, Witwer K […] Fuhrmann G et al. (2019) Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV): an update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 8:1535750
25. Schulz E, Goes A, Panter F, Koch M, Garcia R, Müller R, Fuhrmann K & Fuhrmann G* (2018) Biocompatible bacteria-derived vesicles show inherent antimicrobial activity. Journal of Controlled Release 290:46
24. Fuhrmann G* (2018) Luminal coating of the intestine. Nature Materials 17:754
23. Frank J, Richter M, De Rossi C, Lehr CM, Fuhrmann K & Fuhrmann G* (2018) Extracellular vesicles protect glucuronidase model enzyme during freeze-drying. Scientific Reports 8:12377
22. Goes A & Fuhrmann G* (2018) Biogenic and biomimetic carriers as versatile transporters to treat bacterial infections. ACS Infect Diseases 4:881
21. Fuhrmann G* (2018) Experimental therapies for coeliac diseases. Pharmakon 6(2):44
20. Fuhrmann G, Chandrawati R et al. (2018) Engineering extracellular vesicles with the tools of enzyme prodrug therapy Advanced Materials 30:1706616
This work was featured as back cover in Advanced Materials
19. Fuhrmann K & Fuhrmann G* (2017) Recent advances in oral delivery of macromolecular drugs and benefits of polymer conjugation Current Opinion in Colloid & Interface Science 31:67 (*GF corresponding author)
18. Frank J & Fuhrmann G* (2017) Best before - lyophilisation as novel storage alternative for extracellular vesicles Journal of Extracellular
Vesicles 6:sup1, DOI: 10.1080/20013078.2017.1310414 (*GF
corresponding author)
17. Fuhrmann G*, Neuer AL & Herrmann IK (2017) Extracellular vesicles – a promising avenue for the detection and treatment of infectious diseases? European Journal of Pharmaceutics and Biopharmaceutics 118:56 (*GF sole corresponding author)
16. Fuhrmann G* & Stevens MM (2016) Stability of extracellular vesicles during lyophilisation – implications for their pharmaceutical use. Journal of Extracellular Vesicles 5: 30924-30940 (*GF co-corresponding author)
15. Whittaker T, Fuhrmann G & Stevens MM (2016) Purifying extracellular vesicles by size exclusion: give it a little longer. Journal of Extracellular Vesicles 5: 30924-30940
14. Liu M, Fuhrmann G, Johansen P, Leroux J & Gauthier MA (2016) "Bio-hybrid" therapeutics. Frontiers in Bioengineering and Biotechnology doi: 10.3389/conf.FBIOE.2016.01.00919
13. Santos L, Fuhrmann G, Juenet M, Amdursky N, Horejs C-M, Campagnolo P & Stevens MM (2015) Extracellular stiffness modulates the expression of functional proteins and growth factors in endothelial cells. Advanced Healthcare Materials 4: 2056-2063
12. Fuhrmann G1, Herrmann IK1 & Stevens MM (2015) Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges. Nano Today 10: 397-409 (1GF and IH with equal contribution)
11. Fuhrmann G*, Serio A, Mazo M, Nair R & Stevens MM (2015), Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. Journal of Controlled Release 205: 35-44 (*GF co-corresponding author)
10. Fuhrmann G & Leroux J-C (2014) Improving the stability and activity of oral therapeutic enzymes - recent advances and perspectives. Pharmaceutical Research 31:1099-1105
9. Fuhrmann G, Gauthier MA & Leroux J-C (2013) Polymer-enzyme conjugates for oral drug delivery applications. Chimia 67:685-686
8. Fuhrmann G, Grotzky A, Lukic R, Matoori S, Luciani P, Zhang B, Yu H, Walde P, Schlüter AD, Gauthier MA & Leroux J-C (2013) Sustained gastrointestinal activity of dendronized polymer-enzyme conjugates. Nature Chemistry 5: 582–589.
This work was highlighted in Nature Chemistry News and Views (2013, 5:557–558)
7. Matoori S, Fuhrmann G & Leroux J-C (2012) Celiac disease: a challenging disease for pharmaceutical scientists. Pharmaceutical Research 30:619-626
6. Pinier M, Fuhrmann G, Galipeau H, Rivard H, Murray JA, David CS, Tuckova L, Drasarova H, Leroux J-C & Verdu EF (2012) The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues. Gastroenterology 142: 316-325.e12.
5. Matoori S, Fuhrmann G, Jessica D Schulz & Leroux J-C (2012) Gluten binden und spalten - neue adjuvante Therapiemöglichkeiten für Zöliakie. Swiss Medical Forum 12:716–717
4. Fuhrmann G & Leroux J-C (2011) In vivo fluorescence imaging of exogenous enzyme activity in the gastrointestinal tract. Proceedings of the National Academy of Sciences USA 108:9032-9037.
This work was highlighted in numerous daily newspapers in Germany, Switzerland and Austria, in coeliac disease fora, and in ETH Life (August 2011).
3. Fuhrmann G & Leroux J-C (2010) In vitro evaluation of the stability of proline-specific endopeptidases under simulated gastrointestinal conditions. Journal of Controlled Release 148:e37-e39.
2. Pinier M1, Fuhrmann G1, Verdu E, & Leroux J-C (2010) Prevention measures and exploratory pharmacological treatments of celiac disease. American Journal of Gastroenterology 105:2551-2561 (1MP and GF with equal contribution)
1. Bastiat G, Plourde F, Motulsky A, Furtos A, Dumont Y, Quirion R, Fuhrmann G & Leroux J-C (2010) Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer's disease. Biomaterials 31:6031-6038
Book chapters
2. Fuhrmann G*, Mehanny M* (2024). Spray Drying of Bacterial Membrane Vesicles for Vaccine Delivery. In: Jay, S., Pirolli, N. (eds) Bacterial Extracellular Vesicles. Methods in Molecular Biology, vol 2843. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-4055-5_11
1. Lapuhs P & Fuhrmann G* (2019) Engineering strategies for oral therapeutic enzymes. Advances in Experimental Medicine and Biology (Springer
Nature). In: Labour N (Ed.) Therapeutic Enzymes: Function and Clinical Implications, 151-172, doi.org/10.1007/978-981-13-7709-9